IceCure Medical Calls May 11 Special Meeting to Approve Potential Reverse Share Split

Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The latest announcement is out from Icecure Medical ( (ICCM) ). IceCure Medical has called a special general meeting of shareholders to be held remotely on May 11, 2026, with a record date of April 27, 2026, to vote on a single proposal. The board is seeking shareholder approval for a potential reverse split of the company’s ordinary shares at a ratio between 10:1 and 30:1, to be implemented at the board’s discretion if approved. The board of directors is unanimously recommending a vote in favor of the reverse split authority, which could support the company’s continued compliance with Nasdaq listing standards by boosting the per-share trading price. The notice details voting procedures for both registered and beneficial shareholders, emphasizing that brokers cannot vote uninstructed shares on this non-routine item, making active shareholder participation critical to the outcome. The most recent analyst rating on (ICCM) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page. Spark’s Take on ICCM Stock According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral. The score is held down primarily by weak financial performance (large ongoing losses, heavy cash burn, and shrinking equity) and bearish technicals (price below major moving averages with negative MACD). A more positive earnings-call outlook around regulatory validation and expected commercialization acceleration provides some support, but valuation remains constrained by continued losses and no dividend. To see Spark’s full report on ICCM stock, click here. More about Icecure Medical IceCure Medical Ltd. is an Israel-based medical device company focused on minimally invasive cryoablation technologies for the treatment of tumors. The company’s ordinary shares are listed on the Nasdaq Stock Market, and its shareholder base includes both registered holders and beneficial owners holding through banks and brokers. Average Trading Volume: 447,205 Technical Sentiment Signal: Sell Current Market Cap: $24.87M For a thorough assessment of ICCM stock, go to TipRanks’ Stock Analysis page.